Ursula Wiedermann
Overview
Explore the profile of Ursula Wiedermann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
1480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tobias J, Heinl S, Dendinovic K, Ramic A, Schmid A, Daniel C, et al.
Immunol Lett
. 2025 Jan;
272:106971.
PMID: 39765312
Probiotics have been increasingly recognized for positively influencing many aspects of human health. Lactiplantibacillus plantarum (L. plantarum), a non-pathogenic bacterium, previously known as Lactobacillus plantarum, is one of the lactic...
2.
Jorda A, Prager M, Pracher L, Haselwanter P, Jackwerth M, Al Jalali V, et al.
J Infect
. 2025 Jan;
90(2):106405.
PMID: 39756693
Objectives: There is conflicting evidence as to whether the combined administration of two vaccines can lead to poorer immunogenicity and reactogenicity. The co-administration of the Omicron-adapted COVID-19 vaccine from Novavax...
3.
Tulaeva I, Lehmann F, Goldmann N, Dubovets A, Trifonova D, Tulaev M, et al.
Vaccines (Basel)
. 2024 Oct;
12(10).
PMID: 39460290
Approximately 10-20% of subjects vaccinated with HBsAg-based hepatitis B virus (HBV) vaccines are non-responders. BM32 is a recombinant grass pollen allergy vaccine containing the HBV-derived preS surface antigen as an...
4.
Razim A, Zablocka A, Schmid A, Thaler M, cerny V, Weinmayer T, et al.
J Extracell Vesicles
. 2024 Oct;
13(10):e70004.
PMID: 39429019
Escherichia coli A0 34/86 (EcO83) is a probiotic strain used in newborns to prevent nosocomial infections and diarrhoea. This bacterium stimulates both pro- and anti-inflammatory cytokine production and its intranasal...
5.
McGuinness S, Veit O, Angelin M, Antonini P, Boecken G, Boering M, et al.
J Travel Med
. 2024 Aug;
31(8).
PMID: 39167759
No abstract available.
6.
Tobias J, Steinberger P, Wilkinson J, Klais G, Kundi M, Wiedermann U
Vaccines (Basel)
. 2024 Jul;
12(7).
PMID: 39066432
Immunity against respiratory pathogens is often short-term, and, consequently, there is an unmet need for the effective prevention of such infections. One such infectious disease is coronavirus disease 19 (COVID-19),...
7.
Tobias J, Maglakelidze M, Andric Z, Ryspayeva D, Bulat I, Nikolic I, et al.
Clin Cancer Res
. 2024 Jul;
30(18):4044-4054.
PMID: 39028916
Purpose: A multicenter, randomized, open-label, phase II study (HERIZON; NCT02795988) was conducted to evaluate the clinical and immunologic efficacy of HER-Vaxx (IMU-131), a B-cell, peptide-based vaccine targeting HER2 overexpressed in...
8.
Breiteneder H, Wiedermann U
Allergy
. 2024 Jul;
79(8):2293-2294.
PMID: 38953476
No abstract available.
9.
Wagner A, Garner-Spitzer E, Auer C, Gattinger P, Zwazl I, Platzer R, et al.
Vaccines (Basel)
. 2024 May;
12(5).
PMID: 38793769
Patients with multiple myeloma (MM) are a heterogenous, immunocompromised group with increased risk for COVID-19 morbidity and mortality but impaired responses to primary mRNA SARS-CoV-2 vaccination. The effects of booster...
10.
Sehgal A, Safran J, Kratzer B, Gattinger P, Stieger R, Musiejovsky L, et al.
Vaccines (Basel)
. 2024 Apr;
12(4).
PMID: 38675759
Background: COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has now become endemic and is currently one of the important respiratory virus infections regularly affecting mankind. The assessment...